SecBot SecBot
Biotech Drug Report Generated Jul 13, 2026

EDG-15400

EWTX·Edgewise Therapeutics, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 1
Time to market
Unlikely before 2029-2030 at earliest, Phase 1 data pending, Phase 2 not yet initiated, and HFpEF Phase 3 trials typically take years
Why 4/10
EDG-15400 is in Phase 1 with no hard dated binary catalyst. Phase 1 top-line data was expected H1 2026 (now closed window) but no formal data PR has been issued; Phase 2 HFpEF trial initiation is planned for H2 2026. Neither event is a sharp binary catalyst. The next real catalyst would be Phase 2 efficacy/safety data, not expected until H1 2027 at the earliest. The drug is also a secondary pipeline asset behind EDG-7500 (HCM, Phase 2/3).
Actionable Insight NEUTRAL

EDG-15400 is too early-stage to drive meaningful share price moves in the near term. Watch for the Phase 2 HFpEF trial initiation (expected H2 2026) and eventual Phase 2 data (H1 2027). For EWTX, the more impactful near-term catalyst is the EDG-7500 Phase 3 trial initiation in HCM (Q4 2026). EDG-15400 is a pipeline extension story for now.

Price Chart

Loading chart...

Executive Summary

EDG-15400 is an early-stage (Phase 1) cardiac sarcomere modulator from Edgewise Therapeutics (EWTX) for heart failure with preserved ejection fraction (HFpEF), a large and growing market. After selling its muscular dystrophy program (sevasemten) to Servier for up to $2.65B in mid-2026, Edgewise is now a pure cardiovascular company. EDG-15400 is the second-most-advanced pipeline asset behind EDG-7500 (Phase 2/3 for hypertrophic cardiomyopathy). While the mechanism is novel and the market opportunity is substantial (HFpEF represents roughly half of all heart failure), the drug is years away from commercialization with no near-term binary catalyst that would significantly move the stock.

How It Works

EDG-15400 is a small molecule that selectively modulates the cardiac sarcomere, the heart muscle's basic contracting machinery. It is designed to help the heart muscle relax and fill with blood more efficiently (improving "diastolic function") without weakening the heart's pumping force. This targets the root mechanical problem in HFpEF, a type of heart failure where the heart stiffens and cannot relax properly between beats.

Trial Status

A Phase 1 randomized, double-blind, placebo-controlled single and multiple ascending dose study in healthy adults (NCT07177066) has been enrolling. The study also includes a food-effect/relative bioavailability cohort. Top-line results were expected in H1 2026. A Phase 2 trial in HFpEF patients is planned for H2 2026, with data anticipated in H1 2027. Preclinical data was presented at the ESC Heart Failure 2026 congress showing improved diastolic function in a mini-pig model.

The Two-Sided Case

▲ Bull Case5
Novel mechanism targeting diastolic dysfunction directly, if successful, EDG-15400 would be first-in-class as a cardiac sarcomere modulator for HFpEF, a condition with no disease-modifying therapy that specifically targets the underlying mechanical dysfunction
HFpEF is a massive and growing market (~50% of all heart failure cases, $7.9B heart failure drug market in 2025 projected to reach $21.5B by 2036), and approved therapies like Entresto and SGLT2 inhibitors address it only indirectly
Edgewise is extremely well-capitalized after the $1.55B upfront from Servier (closed July 2026), eliminating financing risk for EDG-15400's development through Phase 2
Preclinical data presented at ESC Heart Failure 2026 showed EDG-15400 improved left ventricular diastolic function and cardiac reserve under stress without impairing systolic function in a relevant animal model
Strong institutional backing, RA Capital ($328M position), Baker Bros. ($207M), BlackRock ($204M), Janus Henderson ($186M) are top holders as of Q1 2026
▼ Bear Case5
Phase 1 top-line data is still unreported as of mid-2026 (target was H1 2026), which raises questions about whether the data was clean, if safety/tolerability issues emerge, the program could be delayed or terminated
EDG-15400 is a secondary pipeline asset for Edgewise behind EDG-7500 (HCM), meaning its development timeline and resource allocation may deprioritize it if EDG-7500 requires more resources
HFpEF is a notoriously difficult indication for drug development, multiple high-profile programs have failed (including Novartis' Entresto struggling in some HFpEF studies), and the condition's heterogeneous patient population makes trial design challenging
The competitive landscape is increasingly crowded with established branded therapies (Novartis' Entresto, BI/Lilly's Jardiance, AstraZeneca's Farxiga) already approved for HFpEF, plus other novel mechanisms in development
Any Phase 2 readout is not expected until H1 2027 at earliest, providing no near-term catalyst for this specific program

Upcoming Catalysts

  • Phase 1 top-line data disclosure (H1 2026 window, potentially imminent or expected soon)
  • Phase 2 trial initiation in HFpEF patients (planned H2 2026)
  • Phase 2 HFpEF efficacy/safety data (expected H1 2027)
  • Preclinical/translational data presentations at cardiology congresses

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Edgewise Therapeutics, Inc. 8-K EWTX ·Originating report

Sources · 12

Hover a chip for the title
1 edgewisetx.com2 clinicaltrials.gov3 biospace.com4 noah.bio5 prnewswire.com6 prnewswire.com7 academic.oup.com8 pharmaphorum.com9 biospace.com10 tipranks.com11 synapse.patsnap.com12 imarcgroup.com